EU Accelerated Assessment Tracker
Executive Summary
BioMarin has secured accelerated assessment at the European Medicines Agency for the planned filing of its potential new gene therapy for severe hemophilia A, Valrox. There was rejection for Amarin's Vascepa. The outcomes of more than a handful of other fast-track requests that companies have made for their planned or recent marketing authorization applications are still unknown.